Editas Medicine Files 2023 Annual Report on Form 10-K

TL;DR

<b>Editas Medicine, Inc. has submitted its 2023 annual report (10-K) detailing its financial and operational status for the year ending December 31, 2023.</b>

AI Summary

Editas Medicine, Inc. (EDIT) filed a Annual Report (10-K) with the SEC on February 28, 2024. Editas Medicine, Inc. filed its 2023 Form 10-K on February 28, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business address is 11 Hurley St., Cambridge, MA 02141. Editas Medicine operates in the Biological Products sector. The filing was made under the Securities Exchange Act of 1934.

Why It Matters

For investors and stakeholders tracking Editas Medicine, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Editas Medicine's financial health, operational activities, and strategic direction for the past fiscal year, which is crucial for investors to assess the company's performance and future prospects. As a biotechnology company focused on gene editing, the details within this filing are essential for understanding its progress in research and development, potential regulatory hurdles, and market positioning within the competitive landscape.

Risk Assessment

Risk Level: medium — Editas Medicine, Inc. shows moderate risk based on this filing. The company operates in the highly regulated and competitive biotechnology sector, with significant R&D expenses and an unproven commercial track record, indicating a medium level of risk.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to assess the company's path to commercialization and long-term viability.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed Period of Report)
• 2024-02-28 — Filing Date (As of Date)
• 102 — Public Document Count (Number of documents in the filing)

Key Players & Entities

• Editas Medicine, Inc. (company) — Filer name
• 2023 (date) — Fiscal year end
• February 28, 2024 (date) — Filing date
• 11 Hurley St., Cambridge, MA 02141 (address) — Business address
• 0001650664 (company) — Central Index Key
• 2836 (industry) — Standard Industrial Classification
• 1934 Act (regulation) — SEC Act
• 001-37687 (identifier) — SEC File Number

FAQ

Industry Context

Editas Medicine operates in the biotechnology industry, specifically focusing on gene editing technologies for therapeutic applications.

Regulatory Implications

The company is subject to regulations from bodies like the FDA concerning the development and approval of novel gene therapies.

What Investors Should Do

1. Analyze the company's financial statements for revenue, expenses, and cash flow.
2. Review the risk factors section for potential challenges and uncertainties.
3. Assess the company's progress on its key drug development programs and clinical trials.

Key Dates

• 2023-12-31: Fiscal Year End — Covers the reporting period for the 10-K filing.
• 2024-02-28: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial analysis of the 2023 10-K filing; comparison to prior filings will require access to those documents.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock , $0.0001 par value per share EDIT The Nasdaq St
• $50.0 million — xagamglogene autotemcel). We received a $50.0 million upfront cash payment and are eligible t
• $10.0 million — ceive annual license fees, ranging from $10.0 million to $40.0 million annually, inclusive of
• $40.0 million — nse fees, ranging from $10.0 million to $40.0 million annually, inclusive of certain sales-ba

Filing Documents

• edit-20231231.htm (10-K) — 1973KB
• ex42-descriptionofcapitals.htm (EX-4.2) — 26KB
• ex107-formincentivestockop.htm (EX-10.07) — 44KB
• ex108-formnonstatutorystoc.htm (EX-10.08) — 41KB
• ex109-formofrestrictedstoc.htm (EX-10.09) — 33KB
• ex1010formofrsuasof2025-02.htm (EX-10.10) — 45KB
• ex1019formofinducementgran.htm (EX-10.19) — 64KB
• ex1020inducementrsugrantag.htm (EX-10.20) — 51KB
• directorcompensationeff202.htm (EX-10.27) — 14KB
• ex1036omnibusamendment.htm (EX-10.36) — 22KB
• ex23110-kconsent.htm (EX-23.1) — 6KB
• edit-20221231xexx311.htm (EX-31.1) — 10KB
• edit-20221231xexx312.htm (EX-31.2) — 10KB
• edit-20221231xexx321.htm (EX-32.1) — 6KB
• ex97clawbackpolicyeff2023-.htm (EX-97) — 21KB
• edit-20231231_g1.jpg (GRAPHIC) — 132KB
• edit-20231231_g2.jpg (GRAPHIC) — 210KB
• image_0.jpg (GRAPHIC) — 0KB
• 0001650664-24-000008.txt (&nbsp;) — 9354KB
• edit-20231231.xsd (EX-101.SCH) — 56KB
• edit-20231231_cal.xml (EX-101.CAL) — 71KB
• edit-20231231_def.xml (EX-101.DEF) — 243KB
• edit-20231231_lab.xml (EX-101.LAB) — 756KB
• edit-20231231_pre.xml (EX-101.PRE) — 488KB
• edit-20231231_htm.xml (XML) — 914KB

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 49 Item 1B. Unresolved Staff Comments 99 Item 1C. Cybersecurity 99 Item 2.

Properties

Properties 100 Item 3.

Legal Proceedings

Legal Proceedings 100 Item 4. Mine Safety Disclosures 100 PART II 101 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 101 Item 6. [Reserved] 102 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 102 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 112 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 113 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 144 Item 9A.

Controls and Procedures

Controls and Procedures 144 Item 9B. Other Information 146 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 146 PART III 146 Item 10. Directors, Executive Officers and Corporate Governance 146 Item 11.

Executive Compensation

Executive Compensation 147 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 147 Item 13. Certain Relationships and Related Transactions, and Director Independence 147 Item 14. Principal Accounting Fees and Services 147 PART IV 148 Item 15. Exhibits and Financial Statement Schedules 148 Item 16. Form 10-K Summary 151

SIGNATURES

SIGNATURES 152 2 Table of Contents References to Editas Throughout this Annual Report on Form 10-K, the "Company," "Editas," "Editas Medicine," "we," "us," and "our," except where the context requires otherwise, refer to Editas Medicine, Inc. and its consolidated subsidiary, and "our board of directors" refers to the board of directors of Editas Medicine, Inc. Special Note Regarding Forward-Looking Statements and Industry Data This Annual Report on Form 10-K contains forward-looking statements regarding, among other things, the initiation, timing, progress and results of our preclinical and clinical studies and our research and development programs, the timing for our receipt and presentation of data from our clinical trials and preclinical studies, potential of, and expectations for, our product candidates, the timing or likelihood of regulatory filings and approvals, our expectations regarding cash runway, and our business strategy, and other objectives for our operations. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. There are a number of important risks and uncertainties that could cause our actual results to differ materially from those indicated by forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the section entitled "Risk Factors" in Part I that could cause actual results or events to differ materially fro

Business

Item 1. Business We are a clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome and by harnessing the progress in technologies for cell therapy, gene therapy, and, most recently, gene editing. We believe this progress sets the stage for us to create medicines with the potential to have a durable benefit for patients. Our core capability in gene editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) to allow us to create molecules that efficiently and specifically edit DNA. Our mission is to translate the promise of gene editing into a broad class of differentiated, transformational medicines for previously untreatable diseases. We have developed a proprietary gene editing platform based on CRISPR technology and we continue to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. Once the complex binds to the DNA sequence it is designed to recognize, the complex makes a specific cut in the DNA. We believe we are the only human genome editing company with a platform that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms of both of these CRISPR systems, and foundational intellectual property for both of these CRISPR systems. Because of the broad nature of this platform, we believe we can create gene editing molecules for over 95% of the human genome. Our Strategy We seek to be a leader in in vivo programmable gene editing, leveraging cutting edge gene editing technology to deliver therapies that simplify the usability for patients, minimize the burdens to patients and healthcare systems, and are

View Full Filing

View this 10-K filing on SEC EDGAR